Affimed to end cancer program and focus on innate immunity portfolio, shares slide about 10% - MarketWatch

in #dlike • 7 years ago

Shared From Dlike

Clinical stage biotech Affimed N.V. said Wednesday it is terminating its phase I program for AFM11 to focus on its innate immunity portfolio. The company had...


Source of shared Link

#dlike-news
7 years ago in #dlike by
100%
    10%25%50%75%100%
    $0.00
    • Max accepted payout: $900.00
    3 votes
    Reply 0